Is Ascentage Pharma Group International (SEHK:6855) Pricing Reflect A 23.3% One‑Year Gain?

Simply Wall St.02-19

If you are wondering whether Ascentage Pharma Group International's current share price still makes sense, this article will walk through how its value stacks up using several common valuation tools. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612547489?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-19 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612547489","market":"us","top_or_hot":-1,"title":"Is Ascentage Pharma Group International (SEHK:6855) Pricing Reflect A 23.3% One‑Year Gain?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Ascentage Pharma Group International's current share price still makes sense, this article will walk through how its value stacks up using several common valuation tools. ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/is-ascentage-pharma-group-international-sehk6855-pricing-ref\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Ascentage Pharma Group International (SEHK:6855) Pricing Reflect A 23.3% One‑Year Gain?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Ascentage Pharma Group International (SEHK:6855) Pricing Reflect A 23.3% One‑Year Gain?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-19 10:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/is-ascentage-pharma-group-international-sehk6855-pricing-ref><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Ascentage Pharma Group International's current share price still makes sense, this article will walk through how its value stacks up using several common valuation tools. ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/is-ascentage-pharma-group-international-sehk6855-pricing-ref\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/is-ascentage-pharma-group-international-sehk6855-pricing-ref","article_id":"2612547489","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/is-ascentage-pharma-group-international-sehk6855-pricing-ref","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612547489","pubTimestamp":1771468088,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Ascentage Pharma Group International's current share price still makes sense, this article will walk through how its value stacks up using several common valuation tools.\nThe stock closed at HK$46.68, with a 7 day return of a 2% decline, a 30 day return of an 8% decline and a 1 year return of 23.3%, which may catch the eye of investors thinking about both risk and opportunity.\nRecent trading interest has been shaped by ongoing attention on the biotech and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK1574":"生物医药B类股","BK1161":"生物科技","06855":"亚盛医药-B"},"translate_title":"亚盛医药集团国际(SEHK：6855)的定价是否反映了23.3%的一年涨幅？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"06855":0.9},"content_text":"If you are wondering whether Ascentage Pharma Group International's current share price still makes sense, this article will walk through how its value stacks up using several common valuation tools. The stock closed at HK$46.68, with a 7 day return of a 2% decline, a 30 day return of an 8% decline and a 1 year return of 23.3%, which may catch the eye of investors thinking about both risk and opportunity. Recent trading interest has been shaped by ongoing attention on the biotech and pharmaceuticals space, where investors often react to clinical progress, regulatory milestones and funding developments. Each news item can move sentiment in the short term. Our focus here is on how these moves line up with a grounded view of what the business may be worth. Our valuation model gives Ascentage Pharma Group International a value score of 2 out of 6, meaning it screens as undervalued on 2 of the 6 checks we run. Next we will compare several valuation approaches before finishing with a broader way to think about what that score really implies.  Ascentage Pharma Group International scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: Ascentage Pharma Group International Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting those back to today’s value. For Ascentage Pharma Group International, this has been done using a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections rather than earnings or dividends. The latest twelve month free cash flow sits at a loss of CN¥246.2 million. Analyst inputs and subsequent extrapolations then map out a path to an expected free cash flow of CN¥1.32 billion in 2030, with further projected figures extending out to 2035. Simply Wall St uses analyst estimates where available, and then extends those forecasts to complete the 2 stage model. When all those future cash flows are discounted back and summed, the model suggests an estimated intrinsic value of HK$295.35 per share. Compared with the recent share price of HK$46.68, the DCF output points to an implied discount of 84.2%. On this metric alone, the shares screen as heavily undervalued. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Ascentage Pharma Group International is undervalued by 84.2%. Track this in your watchlist or portfolio, or discover 223 more high quality undervalued stocks. 6855 Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Ascentage Pharma Group International. Approach 2: Ascentage Pharma Group International Price vs Sales For companies where profits are not yet positive, the P/S ratio is often a useful way to think about value because it compares what you pay for each dollar of revenue, rather than each dollar of earnings. Investors usually accept a higher or lower P/S depending on what they think about future growth and the risks around achieving it. Ascentage Pharma Group International currently trades on a P/S of 38.88x. That sits above both the Biotechs industry average P/S of 14.13x and a peer group average of 12.46x. Simply Wall St also calculates a proprietary “Fair Ratio” for P/S, which is 13.77x for Ascentage Pharma Group International. This Fair Ratio reflects factors such as earnings growth expectations, the company’s industry, profit margins, market cap and identified risks, so it can offer a more tailored yardstick than a simple peer or sector comparison. Because the actual P/S of 38.88x is well above the Fair Ratio of 13.77x, the shares screen as expensive on this measure. Result: OVERVALUED SEHK:6855 P/S Ratio as at Feb 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 103 top founder-led companies. Upgrade Your Decision Making: Choose your Ascentage Pharma Group International Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. These are simply your own story about a company linked directly to numbers like fair value, and your estimates for future revenue, earnings and margins. Narratives are packaged into an easy tool on Simply Wall St’s Community page that helps you compare your Fair Value to the current price, see how that gap might guide your buy or sell decisions, and watch your view update automatically when fresh news or earnings arrive. For Ascentage Pharma Group International, one investor might build a more cautious Narrative that lines up with a lower fair value around HK$51.97, while another might build a more optimistic Narrative closer to HK$92.99. Both investors can clearly see how their different assumptions about future CN¥ earnings, margins and P/E multiples translate into different fair values and different decisions. Do you think there's more to the story for Ascentage Pharma Group International? Head over to our Community to see what others are saying! SEHK:6855 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612547489","isCrawlerRequest":true}